Comparable drug levels and immunogenicity in patients with axial spondyloarthritis treated with adalimumab originator and biosimilar: A retrospective study from two centers of China.

This article discusses the use of biopharmaceuticals, specifically adalimumab, in the treatment of axial spondyloarthritis (axSpA). The study compares the drug levels and immunogenicity of adalimumab originator and a biosimilar called IBI303 in Chinese patients with axSpA. The results show that both drugs had similar efficacy and safety profiles, with no significant differences in drug levels or immunogenicity. The study suggests that biosimilars can be a cost-effective alternative to the originator drug, but further research is needed to evaluate the long-term effects of anti-drug antibody accumulation on drug efficacy. The authors recommend conducting multicenter studies in China to validate the findings. [Extracted from the article]